Compass therapeutics to present at the 2022 h.c. wainwright annual global investment conference

Boston, may 23, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced thomas j. schuetz, m.d., ph.d., co-founder and chief executive officer, is presenting virtually at the 2022 h.c. wainwright global investment conference, occurring may 23-26th, 2022.
CMPX Ratings Summary
CMPX Quant Ranking